Tumor Glycomics Laboratory for Discovery of Pancreatic Cancer Markers

发现胰腺癌标志物的肿瘤糖组学实验室

• 批准号: 7847052
• 负责人: J. Michael Pierce
• 金额: $ 2.38万
• 依托单位: UNIVERSITY OF GEORGIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2009-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7847052
• 关键词: Affinity; Affinity Chromatography; American; Autoantibodies; Biological Assay; Biological Markers; Cancer Control; Cancer Etiology; Cancer Patient; Carbohydrates; Catabolism; Cause of Death; Cessation of life; Clinical; Collaborations; Complex; Complex Mixtures; Coupled; Detection; Development; Diagnosis; Diagnostic; Diagnostic Specificity; Disease; Ductal; Early Detection Research Network; Early Diagnosis; Enzymes; Evaluation; Exhibits; Fourier Transform; Genes; Glycoconjugates; Glycolipids; Glycopeptides; Glycoproteins; Glycosphingolipids; Goals; Hour; Individual; Institutes; Institution; International; Ions; Laboratories; Lectin; Link; Liquid substance; Malignant Neoplasms; Malignant neoplasm of pancreas; Maps; Modification; National Center for Research Resources; Pancreas; Pancreatic Ductal Carcinoma; Pancreatic carcinoma; Pancreatitis; Patients; Polysaccharides; Proteins; Relative (related person); Research; Research Personnel; Sampling; Screening procedure; Sensitivity and Specificity; Serum; Serum Markers; Site; Specialist; Specimen; Structure; Technology; Testing; Tissues; Transcript; Universities; anticancer research; assay development; candidate marker; comparative; instrument; member; mortality; outcome forecast; sample collection; stable isotope; tumor

DESCRIPTION (provided by applicant): Pancreatic cancer is the 4th leading cause of cancer deaths in the U.S. In 2006, 32,180 will be diagnosed with pancreatic cancer and 31,180 will die from it-4 Americans every hour. Pancreatic cancer has the worst 1 and 5 year prognosis of any cancer (4% and 1%, respectively). The high mortality rate for this disease is due mainly to the lack of a means for its early diagnosis. The long-term goal of this RFA application, therefore, is to apply newly developed glycomic technologies to the development of serum markers for pancreatic carcinoma. Pancreatic cancer is somewhat unique in that it is possible to directly collect pancreatic ductal fluid that contains secretions from the cancer which is very likely to contain potential glycoprotein and glycolipid biomarkers. Glycomic analysis of this fluid from pancreatic cancers and control pancreases, coupled with information from pancreatic tissues, including glycotranscriptome analysis, will enable us to focus on specific glyconjugates as potential markers in serum from pancratic cancer patients. Our Tumor Glycomics Laboratory for Pancreatic Cancer represents a collaboration between investigators at the Complex Carbohydrate Research Center at the University of Georgia, including members of the NCRR Center for Biomedical Glycomics, and clinical researchers at the TGen Institute, Phoenix, who are pancreatic cancer specialists. Aims: 1. Glycomic analysis (glycan, glycoprotein, and glycosphingolipid analyses) of pancreatic ductal fluid and controls, including patients with pancreatitis. 2. Glycomic analysis (glycan, glycoprotein, glycosphingolipid, and glycotranscriptome analyses) of pancreatic carcinoma, non-diseased controls, and pancreases exhibiting pancreatitis. 3. Identification of potential serum markers of pancreatic carcinoma and assay development. 4. Initial evaluation specificity and sensitivity of markers. Collection of specimens for analysis will involve TGen and its international Pancreatic Cancer Research Team that involves 26 institutions world-wide, as well as the NCI EDRN for Pancreatic Cancer.

描述（由申请人提供）：胰腺癌是2006年美国癌症死亡的第四个主要原因，将被诊断出32,180个胰腺癌，每小时将死于IT-4美国人。胰腺癌在任何癌症中的预后最差（分别为4％和1％）。该疾病的高死亡率主要是由于缺乏早期诊断的手段。因此，该RFA应用的长期目标是将新开发的糖化技术应用于胰腺癌的血清标记物的开发。胰腺癌在某种程度上是独一无二的，因为可以直接收集胰腺导管液，其中包含癌症的分泌物，这些癌症很可能含有潜在的糖蛋白和糖脂生物标志物。对胰腺癌和控制胰腺的这种液体的血糖分析，再加上胰腺组织中的信息，包括糖司法分析组，将使我们能够将注意力集中在特定的糖缀合物上，作为来自胰腺癌患者血清中的潜在标记。我们的胰腺癌肿瘤糖囊性实验室代表了佐治亚大学复杂碳水化合物研究中心的研究人员之间的合作，包括NCRR生物医学基督教徒中心的成员，凤凰城Tgen Institute的临床研究人员，凤凰城，他们是胰腺癌专家。目的：1。胰腺导管液和对照，包括胰腺炎患者的糖分析（聚糖，糖蛋白和糖磷脂分析）。 2。胰癌，糖蛋白，糖蛋白，糖磷脂和糖胶片分析）的胰腺癌，非疾病对照和胰腺肿瘤表现出胰腺炎。 3。鉴定胰腺癌的潜在血清标志物和测定开发。 4。标记的初始评估特异性和灵敏度。用于分析的标本的收集将涉及TGEN及其国际胰腺癌研究团队，该团队涉及全球26个机构以及NCI EDRN的胰腺癌。